Learners who do not achieve a passing score on a post-activity assessment may take a remediation assessment and/or appeal assessment questions.
Searching for Solutions
Sorry, but this profile is not available.
Browse the posters Download the onsite poster directory
2024 Program Committee and Recertification Editorial Board
Email: info@aapp.org Phone: 402-476-1677 Mailing: 8055 O Street Suite S113 Lincoln, NE 68510
The AAPP 2024 Annual Meeting included valuable insights for psychiatric providers. If you were unable to attend live, you still have the ability to purchase on-demand access to all of the recorded sessions! The price is $685 for Nonmembers and $550 for AAPP Members. Register Now for On-Demand Access!
State of AAPP Report Now Live
The recording of AAPP’s Forum on our Future and answers to the questions posed by members are now posted on the website. Listen in to learn more about the exciting progress at AAPP. Members are welcome to submit questions to board@aapp.org year-round.
Patients living with serious mental illness have complex and growing needs and the behavioral health workforce can't keep pace with the ratcheting demand for services. This issue brief outlines this growing crisis and describes how, similar to the VA model, psychiatric pharmacists can serve as a leading option to expand access to care and assist in filling gaps. Congress must take action to remove barriers to the inclusion of psychiatric pharmacists as outlined in the brief.
Xylazine is a nonopioid veterinary anesthetic that is increasingly detected in the illicit drug supply across the United States. Among opioid-overdose deaths, there has been a dramatic increase in the presence of xylazine. It is now a common additive to substances like fentanyl, heroin and cocaine. Fentanyl Adulterated or Associated with Xylazine (FAAX) was declared an emerging threat on April 12, 2023 by the White House Office of National Drug Control Policy.
What I Wish I Knew: Imposter at Large: Addressing the Impact of Imposter Syndrome
"Combatting self-doubt and recognizing imposter syndrome can be a difficult. As a learner in any stage of your career, it is important to recognize your self-worth and keep striving to build off your experiences" #WIWIK
Respond to the DOJ-Eliminate DEA Prohibition on Prescribing of Methadone - Cloned
Act now! Tell the administration to expand access to lifesaving care by eliminating the DEA’s prohibition on the prescribing of methadone for OUD.
Breaking New Ground Pushing the envelope, charting new territory, blazing trails… all are apt descriptors for AAPP Foundation in 2024 as we not only support our ongoing research and student grants but additionally partner with our parent association, the American Association of Psychiatric Pharmacists (AAPP), to launch the Outcomes Initiative Research Grant Program!
The AAPP Outcomes Initiative grant was awarded during AAPP 2024. In 2023, AAPP committed up to $500,000 to directly support multi-site research related to the impact of psychiatric pharmacists on patient care through the AAPP Foundation. In September of 2023, 6 pre-applications were received and evaluated by the taskforce. After multiple points of feedback, 2 finalists submitted their applications on April 1, 2024.
Research activities may encompass someone's entire role, represent only a small percentage, or be completed on discretionary efforts. Entry into research has many paths. While it may be formal for some (e.g., fellowship, PhD training) it may develop spontaneously from patient specific questions that arise in clinical practice. In academic settings, research may also be pedagogic in nature.
Act Now to Encourage the DOJ to Eliminate DEA Prohibition on Prescribing of Methadone
Join AAPP and other stakeholders in sharing your voice (using the provided toolkit) recommending the elimination of the DEA prohibition on the prescribing of methadone. The DOJ Anticompetitive Regulations Task Force is seeking comment by May 27 on regulations that prevent competition within the health care sector. Current regulation that limits dispensing of methadone for OUD to opioid treatment programs (OTP) is anticompetitive and severely restricts patient access to treatment. Fixing this regulation to allow practitioners to prescribe methadone for OUD that patients can pick up at a local pharmacy would greatly improve patient choice in addiction treatment – especially in cases where methadone is the most effective option for an individual.
Suicide is a global public health concern and a priority of the World Health Organization (WHO) since 2014. It has a devastating impact on communities and families. Psychiatric pharmacists implement evidence-based suicide risk mitigation interventions and are a key part of suicide prevention strategies.
Welcome to AAPP’s resource page. Whether you are seeking information on the treatment of individuals living with mental health and substance use disorders and/or connections in psychiatric pharmacy, this landing page can serve as a starting point for you.